Ignacio Jusué-Torres

Ignacio Jusué-Torres

Auto-generated profile, based on publicly available information

Ignacio Jusué-Torres

Department of Neurosurgery, Mayo Clinic Health System, Eau Claire, WI 54703, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
KCKaisorn L. Chaichana
Kaisorn L. Chaichana
IJIgnacio Jusue-Torres
Ignacio Jusue-Torres
RNRodrigo Navarro-Ramirez
Rodrigo Navarro-Ramirez
SRShaan M. Raza
Shaan M. Raza
MPMaria Pascual-Gallego
Maria Pascual-Gallego
AQAlfredo Quinones-Hinojosa
Alfredo Quinones-Hinojosa
Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goals were to evaluate whether there is an association between EOR and RV with survival and recurrence and to establish minimum EOR and maximum RV thresholds. Adult patients who underwent primary glioblastoma surgery from 2007 to 2011 were retrospectively reviewed. Three-dimensional volumetric tumor measurements were made. Multivariate proportional hazards regression analysis was used to evaluate the relationship between EOR and RV with survival and recurrence. Of 259 patients, 203 (78%) died and 156 (60%) had tumor recurrence. The median survival and progression-free survival were 13.4 and 8.9 months, respectively. The median (interquartile range) pre- and postoperative tumor volumes were 32.2 (14.0–56.3) and 2.1 (0.0–7.9) cm3, respectively. EOR was independently associated with survival (hazard ratio [HR], 0.995; 95% confidence interval [CI]: 0.990–0.998; P = .008) and recurrence (HR [95% CI], 0.992 [0.983–0.998], P = .005). The minimum EOR threshold for survival (P = .0006) and recurrence (P = .005) was 70%. RV was also associated with survival (HR [95% CI], 1.019 [1.006–1.030], P = .004) and recurrence (HR [95% CI], 1.024 [1.001–1.044], P = .03). The maximum RV threshold for survival (P = .01) and recurrence (P = .01) was 5 cm3. This study shows for the first time that both EOR and RV are significantly associated with survival and recurrence, where the thresholds are 70% and 5 cm3, respectively. These findings may help guide surgical and adjuvant therapies aimed at optimizing outcomes for glioblastoma patients.

7 April 2017 in Neurosurgery
Verified
Journal Article
Open access
PDF file
AAAmy Akers
Amy Akers
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
IAIssam A. Awad
Issam A. Awad
KDKristen Dahlem
Kristen Dahlem
KFKelly Flemming
Kelly Flemming
KWKevin Whitehead
Kevin Whitehead
BACKGROUND: Despite many publications about cerebral cavernous malformations (CCMs), controversy remains regarding diagnostic and management strategies. OBJECTIVE: To develop guidelines for CCM management. METHODS: The Angioma Alliance (www.angioma.org), the patient support group in the United States advocating on behalf of patients and research in CCM, convened a multidisciplinary writing group comprising expert CCM clinicians to help summarize the existing literature related to the clinical care of CCM, focusing on 5 topics: (1) epidemiology and natural history, (2) genetic testing and counseling, (3) diagnostic criteria and radiology standards, (4) neurosurgical considerations, and (5) neurological considerations. The group reviewed literature, rated evidence, developed recommendations, and established consensus, controversies, and knowledge gaps according to a prespecified protocol. RESULTS: Of 1270 publications published between January 1, 1983 and September 31, 2014, we selected 98 based on methodological criteria, and identified 38 additional recent or relevant publications. Topic authors used these publications to summarize current knowledge and arrive at 23 consensus management recommendations, which we rated by class (size of effect) and level (estimate of certainty) according to the American Heart Association/American Stroke Association criteria. No recommendation was level A (because of the absence of randomized controlled trials), 11 (48%) were level B, and 12 (52%) were level C. Recommendations were class I in 8 (35%), class II in 10 (43%), and class III in 5 (22%). CONCLUSION: Current evidence supports recommendations for the management of CCM, but their generally low levels and classes mandate further research to better inform clinical practice and update these recommendations. The complete recommendations document, including the criteria for selecting reference citations, a more detailed justification of the respective recommendations, and a summary of controversies and knowledge gaps, was similarly peer reviewed and is available on line www.angioma.org/CCMGuidelines.

13 April 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AHAlicia Hulbert
Alicia Hulbert
IJIgnacio Jusue-Torres
Ignacio Jusue-Torres
ASAlejandro Stark
Alejandro Stark
CCChen Chen
Chen Chen
KRKristen Rodgers
Kristen Rodgers
JHJames G. Herman
James G. Herman
Purpose: CT screening can reduce death from lung cancer. We sought to improve the diagnostic accuracy of lung cancer screening using ultrasensitive methods and a lung cancer–specific gene panel to detect DNA methylation in sputum and plasma. Experimental Design: This is a case–control study of subjects with suspicious nodules on CT imaging. Plasma and sputum were obtained preoperatively. Cases (n = 150) had pathologic confirmation of node-negative (stages I and IIA) non–small cell lung cancer. Controls (n = 60) had non-cancer diagnoses. We detected promoter methylation using quantitative methylation-specific real-time PCR and methylation-on-beads for cancer-specific genes (SOX17, TAC1, HOXA7, CDO1, HOXA9, and ZFP42). Results: DNA methylation was detected in plasma and sputum more frequently in people with cancer compared with controls (P < 0.001) for five of six genes. The sensitivity and specificity for lung cancer diagnosis using the best individual genes was 63% to 86% and 75% to 92% in sputum, respectively, and 65% to 76% and 74% to 84% in plasma, respectively. A three-gene combination of the best individual genes has sensitivity and specificity of 98% and 71% using sputum and 93% and 62% using plasma. Area under the receiver operating curve for this panel was 0.89 [95% confidence interval (CI), 0.80–0.98] in sputum and 0.77 (95% CI, 0.68–0.86) in plasma. Independent blinded random forest prediction models combining gene methylation with clinical information correctly predicted lung cancer in 91% of subjects using sputum detection and 85% of subjects using plasma detection. Conclusions: High diagnostic accuracy for early-stage lung cancer can be obtained using methylated promoter detection in sputum or plasma. Clin Cancer Res; 23(8); 1998–2005. ©2016 AACR.

1 July 2014 in World Neurosurgery
Verified
Journal Article
Closed access
KCKaisorn L. Chaichana
Kaisorn L. Chaichana
ECEibar Ernesto Cabrera-Aldana
Eibar Ernesto Cabrera-Aldana
IJIgnacio Jusue-Torres
Ignacio Jusue-Torres
OWOlindi Wijesekera
Olindi Wijesekera
AOAlessandro Olivi
Alessandro Olivi
AQAlfredo Quinones-Hinojosa
Alfredo Quinones-Hinojosa

6 September 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
KCKaisorn L. Chaichana
Kaisorn L. Chaichana
IJIgnacio Jusue-Torres
Ignacio Jusue-Torres
ALAna Maria Lemos
Ana Maria Lemos
AGAaron Gokaslan
Aaron Gokaslan
ECEibar Ernesto Cabrera-Aldana
Eibar Ernesto Cabrera-Aldana
AQAlfredo Quinones-Hinojosa
Alfredo Quinones-Hinojosa

19 May 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BIN LIUBIN LIU
BIN LIU
JFJulio Ricarte Filho
Julio Ricarte Filho
AMApurva Mallisetty
Apurva Mallisetty
CVCassandra Villani
Cassandra Villani
AKAnastasia Kottorou
Anastasia Kottorou
AHAlicia Hulbert
Alicia Hulbert
Purpose: Low-dose CT screening can reduce lung cancer–related mortality. However, CT screening has an FDR of nearly 96%. We sought to assess whether urine samples can be a source for DNA methylation–based detection of non–small cell lung cancer (NSCLC). Experimental Design: This nested case–control study of subjects with suspicious nodules on CT imaging obtained plasma and urine samples preoperatively. Cases (n = 74) had pathologic confirmation of NSCLC. Controls (n = 27) had a noncancer diagnosis. We detected promoter methylation in plasma and urine samples using methylation on beads and quantitative methylation–specific real-time PCR for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17, and ZFP42). Results: DNA methylation at cancer-specific loci was detected in both plasma and urine, and was more frequent in patients with cancer compared with controls for all six genes in plasma and in CDO1, TAC1, HOXA9, and SOX17 in urine. Univariate and multivariate logistic regression analysis showed that methylation detection in each one of six genes in plasma and CDO1, TAC1, HOXA9, and SOX17 in urine were significantly associated with the diagnosis of NSCLC, independent of age, race, and smoking pack-years. When methylation was detected for three or more genes in both plasma and urine, the sensitivity and specificity for lung cancer diagnosis were 73% and 92%, respectively. Conclusions: DNA methylation–based biomarkers in plasma and urine could be useful as an adjunct to CT screening to guide decision-making regarding further invasive procedures in patients with pulmonary nodules.